AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
from International: Top News And Analysis https://ift.tt/Pq92awf
Wednesday, July 30, 2025
Trump's pharmaceutical tariffs could affect some drugmakers more than others
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment